Trade Merck & Co Inc - USD - MRK CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.20 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Merck & Co Inc ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 105.29 |
Open* | 105.75 |
1-Year Change* | 30.98% |
Day's Range* | 105.68 - 106.32 |
52 wk Range | 72.88-115.49 |
Average Volume (10 days) | 8.08M |
Average Volume (3 months) | 186.31M |
Market Cap | 267.18B |
P/E Ratio | 17.46 |
Shares Outstanding | 2.54B |
Revenue | 58.97B |
EPS | 6.04 |
Dividend (Yield %) | 2.77092 |
Beta | 0.37 |
Next Earnings Date | Feb 2, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 30, 2023 | 106.01 | 0.69 | 0.66% | 105.32 | 106.40 | 105.01 |
Jan 27, 2023 | 105.29 | -0.40 | -0.38% | 105.69 | 106.48 | 105.01 |
Jan 26, 2023 | 106.73 | -1.43 | -1.32% | 108.16 | 108.30 | 105.71 |
Jan 25, 2023 | 108.49 | 1.14 | 1.06% | 107.35 | 109.83 | 107.35 |
Jan 24, 2023 | 108.43 | -0.64 | -0.59% | 109.07 | 109.58 | 107.00 |
Jan 23, 2023 | 109.70 | -0.03 | -0.03% | 109.73 | 110.26 | 109.06 |
Jan 20, 2023 | 109.82 | 0.98 | 0.90% | 108.84 | 109.89 | 108.48 |
Jan 19, 2023 | 109.77 | 2.03 | 1.88% | 107.74 | 110.08 | 107.74 |
Jan 18, 2023 | 108.72 | -1.11 | -1.01% | 109.83 | 110.01 | 108.48 |
Jan 17, 2023 | 110.35 | -1.51 | -1.35% | 111.86 | 112.38 | 110.22 |
Jan 13, 2023 | 112.09 | 1.72 | 1.56% | 110.37 | 112.34 | 110.00 |
Jan 12, 2023 | 111.65 | 1.40 | 1.27% | 110.25 | 112.00 | 109.91 |
Jan 11, 2023 | 110.95 | 2.73 | 2.52% | 108.22 | 111.21 | 108.22 |
Jan 10, 2023 | 110.67 | 1.13 | 1.03% | 109.54 | 111.92 | 109.54 |
Jan 9, 2023 | 110.25 | -4.52 | -3.94% | 114.77 | 114.77 | 109.83 |
Jan 6, 2023 | 114.72 | 0.93 | 0.82% | 113.79 | 115.39 | 113.76 |
Jan 5, 2023 | 113.48 | 2.26 | 2.03% | 111.22 | 113.81 | 111.22 |
Jan 4, 2023 | 111.99 | 0.38 | 0.34% | 111.61 | 112.51 | 111.12 |
Jan 3, 2023 | 111.06 | 0.65 | 0.59% | 110.41 | 111.10 | 109.36 |
Dec 30, 2022 | 110.85 | -0.14 | -0.13% | 110.99 | 111.30 | 110.01 |
Merck & Co Inc - USD Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 39807 | 40122 | 42294 | 39121 | 41518 | 48704 |
Revenue | 39807 | 40122 | 42294 | 39121 | 41518 | 48704 |
Cost of Revenue, Total | 13502 | 12640 | 13065 | 11060 | 11583 | 13241 |
Gross Profit | 26305 | 27482 | 29229 | 28061 | 29935 | 35463 |
Total Operating Expense | 34959 | 34101 | 33995 | 31821 | 36545 | 36166 |
Selling/General/Admin. Expenses, Total | 9844 | 10028 | 10067 | 9421 | 8908 | 9615 |
Research & Development | 6519 | 7495 | 7854 | 8555 | 10102 | 10281 |
Unusual Expense (Income) | 5094 | 3938 | 3009 | 2785 | 5952 | 3029 |
Operating Income | 4848 | 6021 | 8299 | 7300 | 4973 | 12538 |
Interest Income (Expense), Net Non-Operating | -496 | -116 | 10 | -636 | 421 | 873 |
Other, Net | 307 | 616 | 392 | 507 | 469 | 468 |
Net Income Before Taxes | 4659 | 6521 | 8701 | 7171 | 5863 | 13879 |
Net Income After Taxes | 3941 | 5043 | 6482 | 5606 | 4523 | 12358 |
Minority Interest | -21 | -24 | 27 | 84 | -4 | -13 |
Net Income Before Extra. Items | 3920 | 5019 | 6509 | 5690 | 4519 | 12345 |
Net Income | 3920 | 2394 | 6220 | 9843 | 7067 | 13049 |
Income Available to Common Excl. Extra. Items | 3920 | 5019 | 6509 | 5690 | 4519 | 12345 |
Income Available to Common Incl. Extra. Items | 3920 | 2394 | 6220 | 9843 | 7067 | 13049 |
Diluted Net Income | 3920 | 2394 | 6220 | 9843 | 7067 | 13049 |
Diluted Weighted Average Shares | 2787 | 2748 | 2679 | 2580 | 2541 | 2538 |
Diluted EPS Excluding Extraordinary Items | 1.40653 | 1.82642 | 2.42964 | 2.20543 | 1.77843 | 4.86407 |
Dividends per Share - Common Stock Primary Issue | 1.84 | 2.36 | 1.99 | 2.26 | 2.48 | 2.64 |
Diluted Normalized EPS | 6.11554 | 4.03264 | 4.13343 | 3.96379 | 4.69927 | 6.81007 |
Total Extraordinary Items | -2625 | -289 | 4153 | 2548 | 704 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 10627 | 11402 | 13154 | 13521 | 15901 |
Revenue | 10627 | 11402 | 13154 | 13521 | 15901 |
Cost of Revenue, Total | 2984 | 3029 | 3402 | 3827 | 5334 |
Gross Profit | 7643 | 8373 | 9752 | 9694 | 10567 |
Total Operating Expense | 8095 | 9788 | 8338 | 9946 | 10332 |
Selling/General/Admin. Expenses, Total | 2185 | 2279 | 2331 | 2820 | 2302 |
Research & Development | 2404 | 2611 | 2437 | 3061 | 2569 |
Unusual Expense (Income) | 522 | 1869 | 168 | 238 | 127 |
Operating Income | 2532 | 1614 | 4816 | 3575 | 5569 |
Interest Income (Expense), Net Non-Operating | 345 | -27 | 448 | 110 | -983 |
Other, Net | 110 | 130 | 2 | 224 | 275 |
Net Income Before Taxes | 2987 | 1717 | 5266 | 3909 | 4861 |
Net Income After Taxes | 2749 | 1214 | 4571 | 3824 | 4307 |
Minority Interest | -4 | -1 | -4 | -4 | 3 |
Net Income Before Extra. Items | 2745 | 1213 | 4567 | 3820 | 4310 |
Total Extraordinary Items | 434 | 332 | 0 | -62 | 0 |
Net Income | 3179 | 1545 | 4567 | 3758 | 4310 |
Income Available to Common Excl. Extra. Items | 2745 | 1213 | 4567 | 3820 | 4310 |
Income Available to Common Incl. Extra. Items | 3179 | 1545 | 4567 | 3758 | 4310 |
Diluted Net Income | 3179 | 1545 | 4567 | 3758 | 4310 |
Diluted Weighted Average Shares | 2540 | 2540 | 2536 | 2535 | 2537 |
Diluted EPS Excluding Extraordinary Items | 1.08071 | 0.47756 | 1.80087 | 1.5069 | 1.69886 |
Dividends per Share - Common Stock Primary Issue | 0.65 | 0.65 | 0.65 | 0.69 | 0.69 |
Diluted Normalized EPS | 1.44992 | 1.13784 | 2.01068 | 1.9997 | 1.52074 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 30614 | 24766 | 25875 | 27483 | 27764 | 30266 |
Cash and Short Term Investments | 14341 | 8498 | 8864 | 10450 | 8062 | 8096 |
Cash & Equivalents | 6515 | 6092 | 7965 | 9676 | 8062 | 8096 |
Short Term Investments | 7826 | 2406 | 899 | 774 | 0 | |
Total Receivables, Net | 7018 | 6873 | 7071 | 6778 | 7851 | 9230 |
Accounts Receivable - Trade, Net | 7018 | 6873 | 7071 | 6778 | 7851 | 9230 |
Total Inventory | 4866 | 5096 | 5440 | 5978 | 6310 | 5953 |
Other Current Assets, Total | 4389 | 4299 | 4500 | 4277 | 5541 | 6987 |
Total Assets | 95377 | 87872 | 82637 | 84397 | 91588 | 105694 |
Property/Plant/Equipment, Total - Net | 12026 | 12439 | 13291 | 16126 | 17986 | 19279 |
Property/Plant/Equipment, Total - Gross | 27775 | 29041 | 29615 | 33812 | 36968 | 37471 |
Accumulated Depreciation, Total | -15749 | -16602 | -16324 | -17686 | -18982 | -18192 |
Goodwill, Net | 18162 | 18284 | 18253 | 19425 | 20238 | 21264 |
Intangibles, Net | 17305 | 14183 | 11431 | 14196 | 14604 | 22933 |
Long Term Investments | 12131 | 12892 | 6233 | 1889 | 1371 | 966 |
Other Long Term Assets, Total | 5139 | 5308 | 7554 | 5278 | 9625 | 10986 |
Total Current Liabilities | 17204 | 18614 | 22206 | 22220 | 27327 | 23872 |
Accounts Payable | 2807 | 3102 | 3318 | 3738 | 4594 | 4609 |
Accrued Expenses | 10170 | 10263 | 10073 | 12453 | 13053 | 13859 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 568 | 3057 | 5308 | 3610 | 6431 | 2412 |
Other Current Liabilities, Total | 3659 | 2192 | 3507 | 2419 | 3249 | 2992 |
Total Liabilities | 55289 | 53536 | 55936 | 58490 | 66271 | 67510 |
Total Long Term Debt | 24274 | 21353 | 19806 | 22736 | 25360 | 30690 |
Long Term Debt | 24274 | 21353 | 19806 | 22736 | 25360 | 30690 |
Deferred Income Tax | 5077 | 2219 | 1702 | 1470 | 1015 | 3441 |
Minority Interest | 220 | 233 | 181 | 94 | 87 | 73 |
Other Liabilities, Total | 8514 | 11117 | 12041 | 11970 | 12482 | 9434 |
Total Equity | 40088 | 34336 | 26701 | 25907 | 25317 | 38184 |
Common Stock | 1788 | 1788 | 1788 | 1788 | 1788 | 1788 |
Additional Paid-In Capital | 39939 | 39902 | 38808 | 39660 | 39588 | 44238 |
Retained Earnings (Accumulated Deficit) | 44133 | 41350 | 42579 | 46602 | 47362 | 53696 |
Treasury Stock - Common | -40546 | -43794 | -50929 | -55950 | -56787 | -57109 |
Unrealized Gain (Loss) | -3 | -61 | -78 | 18 | 0 | 0 |
Other Equity, Total | -5223 | -4849 | -5467 | -6211 | -6634 | -4429 |
Total Liabilities & Shareholders’ Equity | 95377 | 87872 | 82637 | 84397 | 91588 | 105694 |
Total Common Shares Outstanding | 2748.73 | 2696.61 | 2592.56 | 2539.02 | 2530.23 | 2527.6 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 26909 | 28665 | 31058 | 30266 | 31184 |
Cash and Short Term Investments | 6981 | 8575 | 10016 | 8096 | 8928 |
Cash & Equivalents | 6981 | 8575 | 10016 | 8096 | 8556 |
Total Receivables, Net | 8235 | 7843 | 8571 | 9230 | 9828 |
Accounts Receivable - Trade, Net | 8235 | 7843 | 8571 | 9230 | 9828 |
Total Inventory | 6402 | 5499 | 5603 | 5953 | 5774 |
Other Current Assets, Total | 5291 | 6748 | 6868 | 6987 | 6654 |
Total Assets | 90847 | 90688 | 93494 | 105694 | 106668 |
Property/Plant/Equipment, Total - Net | 18295 | 18064 | 18565 | 19279 | 19747 |
Property/Plant/Equipment, Total - Gross | 37027 | 36300 | 36720 | 37471 | 38245 |
Accumulated Depreciation, Total | -18732 | -18236 | -18155 | -18192 | -18498 |
Goodwill, Net | 20212 | 18873 | 18862 | 21264 | 21258 |
Intangibles, Net | 14401 | 13622 | 13384 | 22933 | 23022 |
Long Term Investments | 1195 | 1105 | 1013 | 966 | 959 |
Other Long Term Assets, Total | 9835 | 10359 | 10612 | 10986 | 10498 |
Total Current Liabilities | 26361 | 21906 | 23728 | 23872 | 22316 |
Accounts Payable | 4034 | 3897 | 3366 | 4609 | 3715 |
Accrued Expenses | 11911 | 12888 | 14214 | 13859 | 14051 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7251 | 2488 | 3534 | 2412 | 1208 |
Other Current Liabilities, Total | 3165 | 2633 | 2614 | 2992 | 3342 |
Total Liabilities | 63902 | 57394 | 57700 | 67510 | 65785 |
Total Long Term Debt | 24002 | 24033 | 22907 | 30690 | 30586 |
Long Term Debt | 24002 | 24033 | 22907 | 30690 | 30586 |
Deferred Income Tax | 1204 | 1489 | 1527 | 3441 | 3071 |
Minority Interest | 94 | 94 | 69 | 73 | 70 |
Other Liabilities, Total | 12241 | 9872 | 9469 | 9434 | 9742 |
Total Equity | 26945 | 33294 | 35794 | 38184 | 40883 |
Common Stock | 1788 | 1788 | 1788 | 1788 | 1788 |
Additional Paid-In Capital | 39613 | 44039 | 44149 | 44238 | 44275 |
Retained Earnings (Accumulated Deficit) | 48888 | 48777 | 51691 | 53696 | 56252 |
Treasury Stock - Common | -56722 | -56682 | -57244 | -57109 | -57063 |
Unrealized Gain (Loss) | 0 | 0 | 0 | 0 | |
Other Equity, Total | -6622 | -4628 | -4590 | -4429 | -4369 |
Total Liabilities & Shareholders’ Equity | 90847 | 90688 | 93494 | 105694 | 106668 |
Total Common Shares Outstanding | 2531.3 | 2532.75 | 2525.32 | 2527.6 | 2528.38 |
Short Term Investments | 372 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 3941 | 2418 | 6193 | 9777 | 4523 | 12358 |
Cash From Operating Activities | 10376 | 6447 | 10922 | 13440 | 10253 | 14109 |
Cash From Operating Activities | 5441 | 4637 | 4519 | 3652 | 1669 | 1578 |
Deferred Taxes | -1521 | -2621 | -509 | -556 | -566 | 187 |
Non-Cash Items | 5116 | 7034 | 2272 | 2634 | 7411 | 2189 |
Cash Taxes Paid | 1800 | 4900 | 1500 | 4500 | 2700 | 2400 |
Cash Interest Paid | 686 | 723 | 777 | 841 | 822 | 779 |
Changes in Working Capital | -2601 | -5021 | -1553 | -2067 | -4601 | -3839 |
Cash From Investing Activities | -3210 | 2679 | 4314 | -2629 | -9443 | -16555 |
Capital Expenditures | -1614 | -1888 | -2615 | -3473 | -4429 | -4448 |
Other Investing Cash Flow Items, Total | -1596 | 4567 | 6929 | 844 | -5014 | -12107 |
Cash From Financing Activities | -9044 | -10006 | -13160 | -8861 | -2832 | 2593 |
Financing Cash Flow Items | -118 | -195 | -325 | 5 | -436 | 8210 |
Total Cash Dividends Paid | -5124 | -5167 | -5172 | -5695 | -6215 | -6610 |
Issuance (Retirement) of Stock, Net | -2495 | -3515 | -8500 | -4419 | -1192 | -638 |
Issuance (Retirement) of Debt, Net | -1307 | -1129 | 837 | 1248 | 5011 | 1631 |
Foreign Exchange Effects | -131 | 457 | -205 | 17 | 253 | -133 |
Net Change in Cash | -2009 | -423 | 1871 | 1967 | -1769 | 14 |
Amortization | 1817 | 1636 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 3186 | 3963 | 8534 | 12358 | 4307 |
Cash From Operating Activities | 1791 | 4281 | 9078 | 14109 | 4761 |
Cash From Operating Activities | 396 | 749 | 1148 | 1578 | 421 |
Amortization | 534 | 871 | 1231 | 1636 | 699 |
Deferred Taxes | -10 | 29 | 28 | 187 | -338 |
Non-Cash Items | -211 | 2324 | 1931 | 2189 | 971 |
Cash Interest Paid | 217 | 363 | 570 | 779 | 211 |
Changes in Working Capital | -2104 | -3655 | -3794 | -3839 | -1299 |
Cash From Investing Activities | -738 | -3445 | -4506 | -16555 | -1173 |
Capital Expenditures | -1134 | -2068 | -3240 | -4448 | -984 |
Other Investing Cash Flow Items, Total | 396 | -1377 | -1266 | -12107 | -189 |
Cash From Financing Activities | -2098 | -340 | -2614 | 2593 | -3086 |
Financing Cash Flow Items | -97 | 8302 | 8243 | 8210 | -103 |
Total Cash Dividends Paid | -1645 | -3318 | -4967 | -6610 | -1745 |
Issuance (Retirement) of Stock, Net | 9 | -188 | -754 | -638 | 12 |
Issuance (Retirement) of Debt, Net | -365 | -5136 | -5136 | 1631 | -1250 |
Foreign Exchange Effects | -97 | -19 | -65 | -133 | -55 |
Net Change in Cash | -1142 | 477 | 1893 | 14 | 447 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7946 | 222977541 | 3070577 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.4365 | 137837792 | 697229 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.6269 | 117311329 | -480300 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8972 | 48100919 | 2106251 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.5839 | 40157172 | -566255 | 2022-09-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2207 | 30950448 | 1429537 | 2022-09-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 1.0307 | 26133153 | -662798 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9382 | 23786901 | -2349731 | 2021-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.8865 | 22475032 | 1102748 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.8749 | 22181659 | 303733 | 2022-09-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.8648 | 21925926 | 114408 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7772 | 19704612 | -575045 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7269 | 18429683 | -1379488 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.7146 | 18119118 | 1683829 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7136 | 18091768 | -228546 | 2022-09-30 | LOW |
Managed Account Advisors LLC | Investment Advisor | 0.7031 | 17825870 | 2268172 | 2022-09-30 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6747 | 17107406 | 366748 | 2022-09-30 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6745 | 17102276 | -39695 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 0.5613 | 14231200 | 0 | 2022-09-30 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 0.5587 | 14166387 | -614838 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Merck - USD Company profile
Merck & Co., Inc. (MRK) is a healthcare company dealing in pharmaceuticals and animal health. Founded in 1891, Merck is headquartered in Kenilworth, New Jersey.
The company provides pharmaceutical products around the world, offering an array of human healthcare solutions designed for areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular and diabetes.
Apart from prescription medicines, Merck is known for its vaccine products for preventive diseases. A predecessor company to the present-day Merck made the first smallpox vaccine for commercial use in the United States in 1898 and was the maker of HPV vaccine Gardasil and painkiller Vioxx.
This biopharmaceutical company engages in research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. In 2021, Merck invested $12.2bn in research and development, especially to counter and help win the fight against coronavirus. It’s molnupiravir was given emergency use authorisation by the United States Food and Drug Administration (FDA) to counter mild-to-moderate Covid-19 in adults.
Merck puts equal emphasis on animal health through Merck Animal Health, a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services.
The company engages and partners with several experts for early-stage science, clinical-stage programs, to deliver therapies and more. GlaxoSmithKline PLC (GSK), Johnson & Johnson (JJ) and many others are actively engaged with Merck.
Being more than a century old, Merck made it through two world wars and was a big part of the economic and business history of American public markets. Post-First World War, authorities seized the subsidiary of a German chemical maker to prevent the Kaiser from profiteering from American needs. Merck was re-established as an American corporation after the Second World War ended.
The company went public on the New York Stock Exchange in 1946 under the symbol ‘MRK’.
Industry: | Pharmaceuticals (NEC) |
2000 Galloping Hill Road
KENILWORTH
NEW JERSEY 07033
US
Income Statement
- Annual
- Quarterly
News

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com